This ad will auto close in 10 seconds
Former promoters of Ranbaxy asked to pay Rs 2,600 crore to Daiichi

Former promoters of Ranbaxy asked to pay Rs 2,600 crore to Daiichi

In a major setback to Malvinder Mohan Singh and Shivinder Mohan Singh, the erstwhile promoters of Ranbaxy Laboratories, the Singapore Court of Arbitration slapped a fine of about Rs 2,600 crore ($400 million) for supressing facts while selling the company to Japanese pharmaceutical company Daiichi Sankyo in 2008

Pharma crusader takes India's drug regulators to court

Pharma crusader takes India's drug regulators to court

Dinesh Thakur's fresh case, a Public Interest Litigation (PIL) suit, is listed on the Supreme Court website for hearing on Friday.


Sun Pharma gets CCI nod to sell two CNS divisions to Strides

Drug major Sun Pharma has received approval from competition watchdog CCI to sell the erstwhile Ranbaxy Laboratories' two divisions in the central nervous system (CNS) segment in India to Strides Shasun for Rs 165 crore.

Sun Pharma looking to divest Ireland plant

"Decisions are being made to either close or divest some of our manufacturing facilities," a Sun Pharma spokesman said in an emailed statement.

Jefferies maintains buy call on Sun Pharma despite adverse guidance

International brokerage house Jefferies said it is positive about Sun Pharma's strong key fundamentals, though its stock plunged 15 percent Tuesday, a day after the company warned of a deeper cut in bottomline and topline this year due to ongoing integration with Ranbaxy.

Sun Pharma shares crash 15%; m-cap dips by Rs 34,055 crore

Shares of Sun Pharma plunged 15 percent Tuesday, wiping out Rs 34,055.55 crore from its market valuation, after the drug major said it expects to take a hit on profit for the fiscal due to charges related to the ongoing integration with Ranbaxy Laboratories.

Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A: Bankers

Sun Pharma, which has a market value of nearly $36 billion, is also interested in non-biotech complex generic medicine.

Sun Pharma shares bounce back, up 3% on bourses

Stocks of Sun Pharmaceutical made a comeback at the bourses Wednesday, rising nearly 3 percent, a day after Japanese drugmaker Daiichi Sankyo sold its entire stake of around 9 per cent in the company for Rs 20,025 crore.

Ranbaxy stock to stop trading on exchanges from next week

Shares of Ranbaxy Laboratories will stop trading on BSE and NSE with effect from April 6 onwards as the company is merging with Sun Pharmaceutical Industries in a USD 4 billion deal.

Ranbaxy ends last trading day on bright note; surges over 5%

Shares of Ranbaxy Laboratories on Wednesday ended with strong gains on the last day of its trade, as the company is being merged with Sun Pharmaceutical in a USD 4 billion deal.

Sun Pharma to delist Ranbaxy on completion of $4 bn merger

The merger has fortified Sun Pharma's position as the world's fifth largest speciality generic pharmaceutical firm.

Sun Pharma gets RBI nod for transfer of Ranbaxy overseas investments

The central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, the filing added.

Ranbaxy merger: Sun Pharma readies new leadership team

Taking forward its acquisition of Ranbaxy Laboratories, Sun Pharma has put in place a team of top executives, including Dilip Shanghvi's son Aalok Shanghvi, to lead the businesses of both the organisations.

HC allows merger of Ranbaxy and Sun pharma

The Punjab and Haryana High Court Monday gave its nod to the merger of two Indian pharmaceutical companies - Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited.

Ranbaxy loses approvals, exclusivity of 2 drugs in US

The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.

Ranbaxy's global HR head Udbhav Ganjoo quits

Ranbaxy Laboratories Global Head of Human Resources Udbhav Ganjoo has resigned from the company and may join multinational pharmaceutical firm Mylan.

Sun Pharma gets US FTC clearance for Ranbaxy acquisition

Sun Pharma gets US FTC clearance for Ranbaxy acquisition

The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition, it added.

Sun Pharma-Ranbaxy deal: US FTC asks Ranbaxy to divest asset

Sun Pharma-Ranbaxy deal: US FTC asks Ranbaxy to divest asset

After Competition Commission of India, US fair trade watchdog FTC has asked Ranbaxy to divest one generic product as a condition for clearing its USD 4 billion deal with Sun Pharma to address monopoly concerns.

Ranbaxy Lab, Sun Pharma gain as CCI clears deal

Ranbaxy Lab's stock rose 4 percent to Rs 650.7 at the BSE.

CCI clears Sun-Ranbaxy deal with riders; asks to divest 7 products

The approval, which comes within days of clearance from theFIPB, for the deal that was announced in April and would create create India's largest and world's fifth biggest drug-maker.